In-vitro diagnostic tests

On September 3, 2026, the National Association of Statutory Health Insurance Physicians (KBV) announced an increase in funding for human genetic diagnostic services reimbursed through the EBM catalog. The decision was adopted by the Evaluation Committee following the completion of its annual review of the volume of development in human genetic services.

In September 2026, the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) is working on 23 projects, including several Med Tech-related assessments concerning the diagnosis of endometriosis, newborn screening, and allergy diagnostic tests.

On August 27, 2026, three medical technologies across the in vitro diagnostics and orthopedics fields received final recommendations from the Regional HTA Commission following the appraisal stage within the Lombardy Regional HTA Program.

In August 2026, the Spanish Network of HTA Agencies published the annual List of New and Emerging Technologies for 2025. The evaluations of a total of 66 technologies, covering multiple areas such as cardiovascular, diagnostic imaging, e-Health, endoscopy, gastrointestinal, in-vitro diagnostics, interventional radiology, men’s health, urology, neurology and neurosurgery, neuromodulation, neurovascular, obstetrics and gynecology, ophthalmology, orthopedics, pulmonary, radiotherapy, spine, and surgical procedures, have been assigned for evaluation to the relevant HTA bodies.

In June 2026, Health Technology Wales (HTW) completed two full appraisals of epileptic seizure alarms and rapid antigen detection tests.

On July 16, 2026, NHS England updated the 2026/27 National Genomic Test Directory (NGTD), initially published in April 2026. The directory lists genomic tests commissioned by NHS England and provided through Genomic Laboratory Hubs. One new test was added to the directory for haematological oncology. Three new multi-target NGS panels, including one ctDNA (liquid biopsy), were added to the directory for non-CNS cancers for carcinoma of unknown primary origin.

In July 2026, an independent review of UK pathology services was published. It covers seven main areas: international experience, the devolved UK nations, quality, workforce, patient access, digital and diagnostic infrastructure, and value and funding. Among the six system-wide priorities, the report recommends aligning digital, workforce, and funding reforms into a single implementation program, moving towards activity-aligned funding through a price-per-test tariff model.

As of July 2026, the Aragon Institute of Health Sciences (IACS), one of Spain’s regional health technology assessment bodies, is conducting several HTAs in areas including diagnostic imaging, digital health, and in vitro diagnostics.

As of July 2026, four medical technologies across e-health, diagnostic imaging, in vitro diagnostics (IVDs), men’s health, and orthopedics fields are awaiting final recommendations from the Regional HTA Commission following completion of the assessment stage within the Lombardy Regional HTA Program.

In June 2026, Health Technology Wales (HTW) accomplished one full appraisal on cone-beam computed tomography for breast imaging in people with suspected breast cancer. Additionally, three Med Tech-related Topic Exploration Reports were published in the fields of e-health and in vitro diagnostics.

On June 11, 2026, the National Association of Statutory Health Insurance Physicians (KBV) announced a number of changes to the reimbursement of human genetics tests to be introduced as of October 1, 2026. The package of changes includes, among other measures, a reduction in the reimbursement values for human genetic services and the introduction of additional volume-based reimbursement reductions at the practice level. These measures are intended to reduce expenditure on human genetic tests by 31%.

In June 2026, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned newborn screening for severe combined immunodeficiency, primary endovascular revascularization procedures for chronic limb-threatening ischemia, placental growth factor (PLGF)-based testing for suspected pre-eclampsia, and digital front door technologies before assessment for NHS Talking Therapies.